Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of OBI-3424 in Subjects With Solid Tumors, Hepatocellular Carcinoma and Castrate-Resistant Prostate Cancer

Trial Profile

A Phase I/II Study of OBI-3424 in Subjects With Solid Tumors, Hepatocellular Carcinoma and Castrate-Resistant Prostate Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Dec 2018

At a glance

  • Drugs OBI 3424 (Primary)
  • Indications Liver cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors OBI Pharma
  • Most Recent Events

    • 09 Jul 2018 According to an OBI Pharma media release, the company has commenced the enrollment in this study at the University of Texas M.D. Anderson Cancer Center.
    • 09 Jul 2018 Status changed from planning to recruiting, according to an OBI Pharma media release.
    • 19 Apr 2018 According to an OBI Pharma media release, the FDA has approved the IND application for Phase I/II study of OBI-3424. This trial will be conducted at the University of Texas M.D. Anderson Cancer Center and The James Cancer Hospital and Solove Research Institute of Ohio State University.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top